Drug resistance patterns and dynamics of tuberculosis in Zhejiang Province, China

Results from five periodic longitudinal surveys

Datos Bibliográficos

ID22082829
AutoresLin Zhou (0000-0002-6428-7392, Zhejiang Center for Disease Control and Prevention), Beibei Wu (0000-0002-4788-0469, Zhejiang Center for Disease Control and Prevention), Fei Huang (0000-0002-3709-5053, Chinese Center For Disease Control and Prevention), Zhengwei Liu (0009-0003-5105-6709, Zhejiang Center for Disease Control and Prevention), Fei Wang (0000-0003-0860-6317, Zhejiang Center for Disease Control and Prevention), Mingwu Zhang (0000-0001-8551-8826, Zhejiang Center for Disease Control and Prevention), Bin Chen (0000-0003-3287-934X, Zhejiang Center for Disease Control and Prevention), Songhua Chen (0000-0002-0858-3664, Zhejiang Center for Disease Control and Prevention, autor de correspondencia), Xiaomeng Wang (0000-0002-2409-2419, Zhejiang Center for Disease Control and Prevention, autor de correspondencia), Yanlin Zhao (0000-0003-2772-3965, Chinese Center For Disease Control and Prevention, autor de correspondencia)
Año2022
Volumen10
Páginas1047659-1047659
Fecha de publicación2022-11-29
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaFrontiers in Public Health (JOURNAL)
Identificadores de la revistaISSN: 2296-2565 • E-ISSN: 2296-2565
EditorialFrontiers Media SA (PUBLISHER • CH)
DOI10.3389/fpubh.2022.1047659
PMID36523585
OpenAlexW4310183415
IdiomaEN
Citas recibidas1
Referencias citadas30

Background: As one of the high multi-drug resistance tuberculosis countries, it is critical for China to understand patterns of drug resistance to better formulate effective treatment regimens. Methods: The anti-TB Drug resistance surveillance has been conducted in Zheijang Province in years 1999, 2004, 2008, 2013, and 2018 respectively. We compared the prevalence of DR-TB from the latest survey with that of the previous four surveys in terms of all four first-line anti-TB drugs. We also examined the prevalence of rifampin-resistant TB (RR-TB) between the last two surveys and routine surveillance data. Results: Among 996 patients surveyed in 2018, the prevalence of RR-TB in new and previously treated TB cases was 2.5 and 4.3%, respectively. The prevalence of RR-TB among previously treated cases was much higher than for new cases in the four surveys from 1999 to 2013, while there was no significant difference between these groups in the 2018 survey. The percentage of TB cases resistant to fluoroquinolones in new patients was 3.8%. The prevalence of non-tuberculous mycobacteria increased over time; the prevalence of RR-TB among new cases slowly decreased. The prevalence of RR-TB in both new and previously treated TB cases from the latest two surveys was consistent with routine surveillance data. Conclusions: This consistency between routine surveillance and periodic surveys for TB cases implies that with universal testing in Zhejiang Province, data from routine surveillance could be used instead of periodic surveys to improve access to timely and appropriate treatment for DR-TB. Levels of resistance were lower than whole-country and global estimates, further indicating the value of universal drug susceptibility testing

China · Drug resistance · Drug resistant tuberculosis · Environmental health · Geography · Mycobacterium tuberculosis · Pathology · Tuberculosis · Demography · Diagnosis and treatment of tuberculosis · Medicine · Pharmaceutical Quality and Counterfeiting · Tuberculosis Research and Epidemiology · Epidemiology · Internal Medicine · Pediatrics